Thelansis

The quiet truth about rare disease medicines is that a brilliant molecule or a one-time gene therapy is only the opening act. Getting the drug from a lab bench miracle into durable, equitable patient benefit now depends on an orchestra of services, diagnostics, payers, and delivery models that work together— an ecosystem, not a product. In this blog, we will walk through why commercial strategy in rare disease is shifting from “sell the drug” to “design the care pathway,” and what that means for launches, payers, and patients. The problem that pushed the shift: scale ≠ standard playbook Rare diseases are heterogeneous by definition, but they share two commercial hard facts: tiny treated populations and, increasingly, very high per-patient costs. An extreme example is one-time gene therapies: pricing can run into the millions of dollars per patient, creating a mismatch with legacy reimbursement systems designed for recurring, lower-cost drugs. These economics force companies and pay...

Why Most RWE Fails Payer Scrutiny (and What Actually Passes) Real-world evidence is no longer optional in market access discussions. Payers expect it. HTA bodies ask for it. Internal teams invest heavily in generating it. And yet, a quiet reality persists: most RWE never meaningfully influences payer decisions. It isn’t rejected outright. It’s acknowledged, parked, and ultimately sidelined. The issue isn’t skepticism toward real-world data. It’s relevant. Too much RWE is built to demonstrate analytical effort rather than to reduce payer uncertainty at the moment a decision is made. Where RWE Goes Wrong The most common failure is simple: RWE answers the wrong question. Many studies focus on describing disease burden, mapping treatment pathways, or validating findings from clinical trials. While useful context, these insights rarely help a payer decide whether to reimburse, restrict, reassess, or expand coverage. Payers are not asking whether a therapy works in theory. They...

Introduction: In recent years, the healthcare landscape has evolved toward an evidence-based, patient-centric architecture. Although conventional clinical trials remain the gold standard, they do not always capture the full gamut of patient experience, follow-up behavior, and the long-term impact of standard-of-care practices observed in real-world settings. To bridge this gap, our team leveraged Real-World Evidence (RWE) analytics and transformed patient data into regulatory-grade insights to support faster approvals and lifecycle management of therapies. Client Overview: A mid-sized biopharmaceutical company developing an orphan drug for a rare metabolic disorder approached Thelansis to strengthen its regulatory submission with RWE. While the client’s Phase III trial demonstrated efficacy in controlled settings, regulators requested additional post-market and real-world validation to understand long-term safety and treatment effectiveness across a broader population. The cl...